Navigation Links
Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
Date:12/28/2007

cent (20%) of patients experienced at least 1 episode of greater than or equal to Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), asthenic conditions (3%) and thrombocytopenia and diarrhea (each 2%). In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus DOXIL study.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is http://www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and developme
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
2. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
3. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
4. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
5. Life Sciences Leader Joins Millennium Board of Directors
6. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
7. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
8. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
9. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
10. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LOUIS , Sept. 18, 2014  U.S. biotech ... by signing an exclusive license for technology developed by ... control gene expression in plants, including for applications in ... The technology was developed under the ... officer at Kultevat and former president of the Danforth ...
(Date:9/18/2014)...  Neogen Corporation (Nasdaq: NEOG ) announced ... with Merck Animal Health to market Neogen,s Igenity ® ... Dairy Heifer Program consists of genomic tests that offer ... of replacement dairy heifers. The genomic tests can be ... an excellent tool in the decision-making process for breeding ...
(Date:9/18/2014)... YARDLEY , Pennsylvanie, 18 septembre 2014 ... Lyon en 1974, a été ... à compléter les évaluations cliniques traditionnelles par ... Reported Outcomes) et sur les impacts économiques ... http://photos.prnewswire.com/prnh/20140618/119365 A cours ...
(Date:9/18/2014)... OMICS Group International invites researchers, authors and ... ‘Open Access Week’ by actively contributing their research ... Journals from 20-26th October, 2014. , Pharmaceutical ... accelerating with a tremendous speed to provide improved ... industry is gearing with innovation and technological revolution ...
Breaking Biology Technology:Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 21974 - 2014 - Mapi fête ses 40 ans 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... Feb. 21 AstraZeneca,believes this lawsuit is legally and ... Supreme Court, if the trial court does not reject ... premise that the,Alabama State Medicaid Agency did not understand ... We believe numerous errors occurred during the proceedings ...
... Today, Nycomed US Inc.,successfully completed the acquisition ... therapeutic markets in the United States. With,this acquisition, ... offered through its PharmaDerm Division and thereby increase,market ... Fougera,Division, which is a leader in the topical ...
... Cardinal Health, a,global provider of products and services ... announced an order by the New York,Department of Health ... expanding statewide plan to maintain emergency response readiness, New,York ... over the past two years., Cardinal Health has ...
Cached Biology Technology:Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc. 2New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 2
(Date:9/18/2014)... world-leading provider of scientific, technical and medical information ... Society (ARMS), recognized the academic research achievements of ... Researcher of the Year Awards. , The award ... Centre and in conjunction with the ARMS 2014 ... and New Zealand,s scientific community. Guest of honour ...
(Date:9/18/2014)... can swim up to 400 kilometres in search of a ... change. , Clownfish spend their entire adult lives under the ... wander the open ocean, says study co-author, Dr Hugo Harrison ... (Coral CoE) at James Cook University. , "In the past ... given a rare glimpse into how far they can swim, ...
(Date:9/17/2014)... the Arts and Humanities has received a $260,000 grant ... project, "The Boundaries of the Human in the Age ... a wide-ranging series of events aimed at exploring two ... artists and researchers who are exploring the boundaries of ... humanism, and the other involves the increasingly influential hypothesis ...
Breaking Biology News(10 mins):Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Nemo's epic journey to find a new home 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... 31 January 2014 VIB and CD3 (KU Leuven) ... agreement with AstraZeneca for the development of novel MALT1 ... The research teams of Thijs Baens and Peter ... Beyaert (VIB-UGent, Inflammation Research Center) were among the first ...
... University have just published a comprehensive overview of forensic research ... "By pulling all of this information together in one ... some children and find justice for others," says Dr. Ann ... author of the paper. Ross is also co-editor of the ...
... were domesticated more than 15,000 years ago and it ... to form close relationships with humans stems from changes ... on the interactions between the animals have not received ... Range and Zsfia Virnyi, two members of the University ...
Cached Biology News:VIB&CD3 enter into license and collaboration agreement with AstraZeneca for development of MALT1 inhibitor 2Forensic experts compile guide on how to ID child abuse, starvation 2Teaching young wolves new tricks 2
...
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Mycoplasma and virus tested...
Biology Products: